JAMA
October 26, 2026
David Feifel, Mathieu Seynaeve, Wiesław Jerzy Cubała et al.
Psychedelics represent a potential breakthrough for treatment-resistant depression; however, the prolonged in-clinic monitoring required for compounds such as psilocybin and lysergic acid diethylamide is a logistical hurdle to widespread use. Intranasal mebufotenin (5-methoxy-N,N-dimethyltryptamine), a 5-hydroxytryptamine 1A (5-HT1A) and 5-HT2A agonist associated with brief psychedelic...
Alcoholism & Drug Abuse Weekly
October 16, 2026
Alison Knopf
A nationally representative cross‐sectional survey of U.S. adults found the among all psychedelics, ibogaine and 5‐MeO‐DMT (5‐methoxy‐N,N‐ dimethyltryptamine) resulted in the most frequent self‐reported adverse outcomes, according to a recent study. The study, “Adverse Health Outcomes of Psilocybin, LSD, MDMA, Ibogaine, and 5‐MeO‐DMT,” by Otto Simonsson, Ph.D., and colleagues, was published...
L'Encephale
October 16, 2026
Anne Buot, Jean-Del Burdairon, Luc Mallet et al.
The use of psychedelic substances such as LSD, psilocybin, and dimethyltryptamine is currently being re-evaluated for their therapeutic potential in psychiatry. While international clinical research had started in the 2010s, France only initiated its first psychedelic trials in 2024. This study aimed to explore the knowledge, perceptions, and attitudes of French mental health professionals...
Trials
October 14, 2026
Luca Pani, Fabio Tascedda
Abstract: Background: The registry record of psychedelic and related rapid-acting compounds is large, heterogeneous and laborious to synthesize by hand. We tested whether a large language model (LLM) with live access to the ClinicalTrials.gov application programming interface (API) could produce a timely, structured and reproducible characterization of this landscape. Methods: Cross-sectional...
Lviv University Herald Series Psychological sciences
October 12, 2026
Ruslan Hanushchak, Игорь Прись
У статті здійснено ретроспективний огляд розвитку психоделічної терапії та проаналізовано сучасний стан досліджень її ефективності у лікуванні психічних розладів. Простежено еволюцію використання психоделічних речовин – від традиційних духовних і лікувальних практик корінних народів через ранні клінічні дослідження середини ХХ століття до сучасного етапу, так званого «психоделічного ренесансу»....
Psychiatry and Clinical Psychopharmacology
October 11, 2026
Kim Supit, Giordano N. Rossi, José Augusto S. Reis et al.
Background: Classic psychedelics, including LSD, psilocybin, and N,N-dimethyltryptamine (DMT)/ ayahuasca, have shown promise as rapid-acting treatments for psychiatric disorders. Because sleep plays a central role in emotional regulation and neuroplasticity, psychedelic-induced changes in sleep architecture are of interest.Methods: A systematic review was conducted following PRISMA guidelines....
Cortica
October 10, 2026
Ayla Gay
Altered states of consciousness (ASCs) induced by psychological practices (mindfulness meditation, hypnosis, self-induced trance) and pharmacological agents (classical and atypical psychedelics) are increasingly linked to therapeutic change, yet their shared and unique neural signatures remain uncertain. We conducted three preregistered, coordinate-based meta-analyses using SDM-PSI, mindfulness...
Surgical Neurology International
October 9, 2026
Andrea Garcia-Bitar, Eduardo Jesus Castañeda, José Rafael Buenrostro-Rangel et al.
Background: Neurosurgical patients carry a high and frequently undertreated burden of psychological suffering, acute and chronic pain, and neurological deficits amenable to recovery. The resurgence of psychedelic research has produced relevant evidence in adjacent fields, but its applicability to neurosurgery has not been systematized. This review synthesizes that evidence across prevention,...
Therapeutic Advances in Psychopharmacology
October 8, 2026
Gianluca A. Florineth, Anna L. Boeker, Felix Müller et al.
Background Classic psychedelics show potential for treating psychiatric disorders, yet the psychological framework of psychedelic-assisted therapy (PAT) remains underspecified. As regulatory approval approaches, defining the contribution of psychological interventions to clinical outcomes is critical for both mechanism inference and implementation. Objectives To systematically review the...
Molecular Psychiatry
October 3, 2026
Xiubo Du, Feiyuan Peng, Xiaohui Wang
Disorders of consciousness (DoC), including coma, unresponsive wakefulness syndrome (also known as vegetative state), and minimally conscious state, represent profound disruptions in awareness and responsiveness due to severe brain injury, with limited therapeutic options available. Recent advancements in neuroimaging have improved our ability to detect residual brain activity in DoC patients,...